[用0.02%的局部丝裂霉素C治疗结膜上皮内瘤变]
[Treatment of conjunctival intraepithelial neoplasia with topical mitomycin C 0.02%].
作者信息
Ramos-López J F, Martínez-Costa Pérez R, Cisneros Lanuza A L, Francés Muñoz E, Monte Boque E, Muñoz Gómez M C, López-Sánchez E V, Menezo Rozalén J L
机构信息
Hospital Universitario La Fe y Fundación Oftalmológica del Mediterráneo (FOM), Valencia, España.
出版信息
Arch Soc Esp Oftalmol. 2004 Aug;79(8):375-8. doi: 10.4321/s0365-66912004000800004.
PURPOSE
To evaluate the efficacy of topical mitomycin C (MMC) 0.02% in treating conjunctival intraepithelial neoplasia (CIN).
METHODS
Three patients with CIN were treated with topical MMC 0.02%. Our follow-up period was twelve months (range 8-18 months).
RESULTS
CIN was resolved in all three cases without modifying the normal corneal and conjunctival architecture.
CONCLUSIONS
Topical MMC 0.02% four times daily during two weeks is a useful alternative tool for the surgical management of CIN.
目的
评估0.02%的局部丝裂霉素C（MMC）治疗结膜上皮内瘤（CIN）的疗效。
方法
3例CIN患者接受了0.02%的局部MMC治疗。我们的随访期为12个月（范围8 - 18个月）。
结果
所有3例CIN均得到解决，且未改变正常角膜和结膜结构。
结论
两周内每日4次使用0.02%的局部MMC是CIN手术治疗的一种有效替代方法。
Zotero 插件